Category: Lab Notes: Cancer Biology
Cbl‑b
Cbl‑b is a single‑chain RING finger ubiquitin ligase that acts as a master regulator of immune activation. By ubiquitinating key signalling molecules in T‑cells, B‑cells and NK cells, Cbl‑b maintains immune tolerance and prevents hyperactivation. Loss of Cbl‑b leads to autoimmunity and enhanced anti‑tumour immunity, making it a critical player in immune homeostasis and a promising target in cancer immunotherapy.
CBL Family Ubiquitin Ligase
The CBL family of ubiquitin ligases—c‑Cbl, Cbl‑b and Cbl‑c—are single‑chain RING finger E3 enzymes that regulate receptor tyrosine kinase signalling, immune activation and epithelial homeostasis. Through their TKB and RING domains, CBL proteins control ubiquitination, endocytosis and signal attenuation. Dysregulation of CBL ligases contributes to cancer, autoimmunity and inflammatory disorders, highlighting their importance in cellular regulation and disease.
RNF115 (RING Finger Protein 115)
RNF115 (BCA2) is a dual RING/U‑box E3 ubiquitin ligase that regulates membrane trafficking, innate immunity and antiviral defence. By ubiquitinating BST‑2/Tetherin, Rab7‑associated endosomal proteins and EGFR, RNF115 influences receptor turnover, immune signalling and cancer progression, making it a key regulator of cellular homeostasis.
U‑Box Ubiquitin Ligase
U‑box ubiquitin ligases are RING‑type E3 enzymes with a modified U‑box domain that enables zinc‑independent ubiquitin transfer. Key members such as CHIP, PRPF19 and UBOX5 regulate chaperone‑mediated protein quality control, DNA‑damage repair and cellular stress responses, making the U‑box family essential for proteostasis and genome stability.
RBR Ubiquitin Ligase
RBR ubiquitin ligases are hybrid E3 enzymes that combine RING‑type E2 binding with HECT‑like catalytic ubiquitin transfer. Through key members such as Parkin, HHARI and HOIP, the RBR family regulates mitophagy, protein‑quality control and M1‑linked ubiquitination in immune signalling, making them central to cellular stress responses and disease mechanisms.
Ubiquitin–Proteasome System (UPS) in Cancer
The ubiquitin–proteasome system (UPS) regulates protein turnover and controls cell‑cycle progression, DNA repair, apoptosis and oncogenic signalling. In cancer, UPS components become dysregulated, leading to excessive degradation of tumour suppressors and stabilisation of oncogenic proteins. This imbalance drives tumour growth and makes UPS a powerful therapeutic target.
Cancer
Cancer is a multifaceted disease caused by the uncontrolled growth of abnormal cells. It develops through genetic and epigenetic alterations, environmental exposures, and interactions within the tumour microenvironment. Understanding these processes is essential for improving prevention, diagnosis, and treatment.
